Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 61

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 61
---
 determined
according to the formula set forth in the warrant. No fractional shares of common stock will be issued in connection with the exercise
of a warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the
exercise price.

Exercise Limitation.A
holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates and certain related
parties) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common stock
outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of
the warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the
61st day after notice of such election is provided to us.

Exercise Price. The
warrants will have an exercise price of $2.19 per share. The exercise price is subject to appropriate adjustment in the event
of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common
stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.

| 35 |

Transferability. Subject
to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.

Exchange Listing. There
is no established trading market for the warrants and we do not expect a market to develop. In addition, we do not intend to apply for
the listing of the warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity
of the warrants will be limited.

Fundamental Transactions. If
a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and
power that we may exercise and will assume all of our obligations under the warrants with the same effect as if such successor entity
had been named in the warrant itself. If holders of our common stock are given a choice as to the securities, cash or property to be received
in a fundamental transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of
the warrant following such fundamental transaction. In addition, in the event of a fundamental transaction which is within our control
and approved by our Board of Directors, the holders of warrants have the right to require